\n ![\"The](\"https:\/\/www.tbsnews.net\/sites\/all\/themes\/sloth\/images\/google_news.svg\")
\n Keep updated, follow The Business Standard’s Google news channel
\n <\/a><\/p>\nAn infographic from The Business Standard details the corporate profile and financial strength of Renata PLC, showing key metrics including turnover, profit after tax, and net asset value per share from FY20 to FY24. | Infograph: TBS<\/p>\n
“> <\/p>\n
![\"Infographic](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/1761759679_646_1.png\" "\\"Renata")
<\/p>\n
An infographic from The Business Standard details the corporate profile and financial strength of Renata PLC, showing key metrics including turnover, profit after tax, and net asset value per share from FY20 to FY24. | Infograph: TBS<\/p>\n
Renata currently produces 83 bioequivalent products. While the concept may sound complex, it is straightforward. When a patient takes a medicine, there is usually an “innovator drug” \u2014 the original \u2014 and a generic version. Bioequivalence proves that both perform identically in the body, guaranteeing safety, efficacy, and therapeutic effect. This is vital for antibiotics, chemotherapy, and long-term treatments. In Bangladesh, it ensures that people in Comilla, Sylhet, or any other city have access to the same quality medicines available in developed countries.\n<\/p>\n
Innovation is central to our strategy. Internationally, we recently launched a drug in Australia with a unique dosage form developed entirely by Renata. Domestically, we identified a challenge: nurses and clinicians struggled to reconstitute powdered cancer drugs safely. To solve this, we developed ready-to-use injections that remain stable at room temperature, requiring no refrigeration or extra preparation. This innovation saves time, reduces risk, and lowers costs.<\/p>\n
We also focus on paediatric oncology. Many drugs are formulated for adults, making safe administration to children extremely difficult. We developed titratable versions that can be adjusted for individual weights and dosages. We conducted clinical trials, proved efficacy and safety, and patented the formulations under Renata’s name. While we are not yet full-fledged innovators, these steps pave the way for Renata to become one.<\/p>\n
I often follow global pharmaceutical developments and dream of a future where people ask: “What new drug has Renata come out with?” This vision motivates me every day. What excites me most is that these innovations are driven by young talent in Bangladesh. Providing them with platforms and opportunities is critical; otherwise, they may move abroad. Empowered, they will take the industry further than we ever imagined.<\/p>\n
I am optimistic about Bangladesh’s pharmaceutical industry. With dedication, ethical practices, and focus on research and development, I believe we are moving in the right direction. Renata is well-positioned to be recognised as a science-led, globally competitive company. Our mission remains clear: to deliver world-class medicines to our people while contributing meaningfully to global healthcare. This is both our responsibility and our ambition, and I am proud to be part of it.<\/p>\n","protected":false},"excerpt":{"rendered":"From stroke medications in Australia to ready-to-use cancer injections at home, Renata\u2019s innovations reflect its mission to deliver…\n","protected":false},"author":2,"featured_media":151852,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[34527,88578,88919,31416,18,14480,88921,16523,135,475,474,88918,19,76358,3536,17,30801,88917,88920],"class_list":{"0":"post-151851","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-animal-health","9":"tag-bangladesh-pharmaceutical-industry","10":"tag-bioequivalent-products","11":"tag-business-growth","12":"tag-eire","13":"tag-financial-performance","14":"tag-financial-strength","15":"tag-global-exports","16":"tag-health","17":"tag-health-care","18":"tag-healthcare","19":"tag-human-pharmaceuticals","20":"tag-ie","21":"tag-infographic","22":"tag-innovation","23":"tag-ireland","24":"tag-rd","25":"tag-renata-plc","26":"tag-syed-omar-kabir"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115458689313098443","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/151851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=151851"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/151851\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/151852"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=151851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=151851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=151851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Syed](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/10\/syed_omar_kabir_supplement.jpg\" "\\"\\"\/")
<\/p>\n